Checchi Capital Advisers LLC Decreases Holdings in Novo Nordisk A/S (NYSE:NVO)

Checchi Capital Advisers LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,309 shares of the company’s stock after selling 162 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Novo Nordisk A/S were worth $2,177,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Impact Investors Inc bought a new position in Novo Nordisk A/S during the fourth quarter valued at $430,000. Cutter & CO Brokerage Inc. increased its holdings in Novo Nordisk A/S by 2.9% in the 4th quarter. Cutter & CO Brokerage Inc. now owns 290,101 shares of the company’s stock worth $24,954,000 after acquiring an additional 8,306 shares during the last quarter. Lake Street Advisors Group LLC lifted its holdings in Novo Nordisk A/S by 5.5% during the fourth quarter. Lake Street Advisors Group LLC now owns 15,470 shares of the company’s stock valued at $1,331,000 after purchasing an additional 811 shares during the last quarter. Cavalier Investments LLC increased its stake in shares of Novo Nordisk A/S by 4.3% in the fourth quarter. Cavalier Investments LLC now owns 23,429 shares of the company’s stock worth $2,015,000 after purchasing an additional 960 shares in the last quarter. Finally, Edge Capital Group LLC raised its position in shares of Novo Nordisk A/S by 1.1% in the fourth quarter. Edge Capital Group LLC now owns 58,465 shares of the company’s stock valued at $5,029,000 after purchasing an additional 635 shares during the period. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on NVO shares. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

NVO opened at $90.94 on Wednesday. The stock has a fifty day simple moving average of $85.32 and a two-hundred day simple moving average of $107.42. The company has a market cap of $408.07 billion, a price-to-earnings ratio of 27.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.